Wed. 8 May 2024, 7:29am ET
Benzinga
Earnings, Earnings Beats, Earnings Misses, News
Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. The company reported quarterly sales of $3.425 million which missed the analyst consensus estimate of $3.764 million by 8.99 percent. This is a 18.96 percent increase over sales of $2.879 million the same period last year.